LublinFDReingoldSC. Defining the clinical course of multiple sclerosis: results of an international survey. Neurology1996; 46: 907–911.
2.
MarrieRARudickR. Drug insight: interferon treatment in multiple sclerosis. Nat Clin Pract Neurol2006; 2: 34–44.
3.
KalbR.The emotional and psychological impact of multiple sclerosis relapses. J Neurol Sci2007; 256: S29–S33.
4.
O’BrienJWardAPatrickA. Cost of managing an episode of relapse in multiple sclerosis in the United States. BMC Health Serv Res2003; 3: 17.
5.
TedeholmHLyckeJSkoogB. Time to secondary progression in patients with multiple sclerosis treated with first generation immunomodulating drugs and historical controls, adjusted for clinical covariates. Mult Scler2012 [Epub ahead of print].
6.
BergamaschiRQuagliniSTavazziE. Immunomodulatory therapies delay disease progression in multiple sclerosis. Mult Scler2012 [Epub ahead of print].
7.
ShiraniAZhaoYKarimM. Association between use of interferon beta and progression of disability in patients with relapsing-remitting multiple sclerosis. JAMA2012; 308: 247–256.
8.
CeliusEGSmestadC. Change in sex ratio, disease course and age at diagnosis in Oslo MS patients through seven decades. Acta Neurol Scand2009; 120: 27–29.
9.
SacksHChalmersTSmithHJ. Randomized versus historical controls for clinical trials. Am J Med1982; 72: 233–240.
10.
ConcatoJShahNHorwitzRI. Randomized, controlled trials, observational studies, and the hierarchy of research designs. N Engl J Med2000; 342: 1887–1892.
